Natera Inc - Company Profile
Powered by 
All the sales intelligence you need on Natera Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Natera Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Natera Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Natera Inc (Natera) develops genetic and cell-free deoxyribonucleic acid (cfDNA) testing solutions. The company’s products include Signatera, a personalized ctDNA (circulating tumor DNA) blood test to assess MRD (molecular residual disease), and its recurrence; Aletra, a tissue-based genomic profiling test to identify genomic alterations and oncology biomarkers in a tumor; Prospera, a transplant rejection test to evaluate the risk of rejection of a transplanted kidney. It also offers a Renasight test to detect the genetic causes of kidney diseases, Horizon carrier screening test, Panorama non-invasive prenatal screening test, Empower hereditary cancer test, Vistara prenatal single gene screening test, Anora miscarriage test and Spectrum preimplantation genetic test. Natera is headquartered in Austin, Texas, the US.
Headquarters
United States of America
Address
Building A, Suite 100, 13011 Mccallen Pass, Austin, Texas, 78753
Website
www.natera.com
Telephone
1 650 9809190
No of Employees
6,135
Industry
Medical Equipment
Ticker Symbol & Exchange
NTRA (NASD)
Revenue (2024)
$2.3B
35.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-9.3%
(2024 vs 2023)
Market Cap*
$40.0B
Net Profit Margin (2024)
XYZ
19.5%
(2024 vs 2023)
* As of and is in US$
Natera Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Signatera: | natera |
| Circulating Tumor DNA Blood Test | Signatera |
| Prospera: | Prospera |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company signed a partnership with CytoDyn to assess circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights. |
| 2026 | Regulatory Approval | In May, the company received approval from the U.S. Food and Drug Administration for Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq) immunotherapy in MIBC. |
| 2026 | Plans/Strategy | In May, the company announced plans to open a second facility and new lab space in Austin. |
Competitor Comparison
| Key Parameters | Natera Inc | Exact Sciences Corp | Guardant Health Inc | Adaptive Biotechnologies Corp | Personal Genome Diagnostics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Austin | Madison | Palo Alto | Seattle | Baltimore |
| State/Province | Texas | Wisconsin | California | Washington | Maryland |
| No. of Employees | 6,135 | 7,200 | 2,490 | 624 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Matthew Rabinowitz, Ph.D. | Chairman | Executive Board | 2019 | 53 |
| Steven Chapman | Director; Chief Executive Officer; President | Executive Board | 2019 | 47 |
| Michael B. Brophy | Chief Financial Officer | Senior Management | 2017 | 45 |
| Olesya Anisimova | Chief Accounting Officer | Senior Management | 2022 | - |
| Rishi Kacker | Chief Technology Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer